{"id":"cinromide","rwe":[{"pmid":"33825230","year":"2021","title":"Anti-seizure medications for Lennox-Gastaut syndrome.","finding":"","journal":"The Cochrane database of systematic reviews","studyType":"Clinical Study"},{"pmid":"30589598","year":"2019","title":"Identification and Characterization of Inhibitors of a Neutral Amino Acid Transporter, SLC6A19, Using Two Functional Cell-Based Assays.","finding":"","journal":"SLAS discovery : advancing life sciences R & D","studyType":"Clinical Study"},{"pmid":"2700841","year":"1989","title":"[Lennox-Gestaut syndrome: therapeutic aspects].","finding":"","journal":"Rivista di neurologia","studyType":"Clinical Study"},{"pmid":"2666120","year":"1989","title":"Double-blind, placebo-controlled evaluation of cinromide in patients with the Lennox-Gastaut Syndrome. The Group for the Evaluation of Cinromide in the Lennox-Gastaut Syndrome.","finding":"","journal":"Epilepsia","studyType":"Clinical Study"},{"pmid":"2975002","year":"1988","title":"Influence of cinromide on metrazol--induced seizures during ontogenesis in rats.","finding":"","journal":"Physiologia Bohemoslovaca","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Sodium-dependent neutral amino acid transporter B(0)AT1","category":"target"},{"label":"SLC6A19","category":"gene"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"vumide","offLabel":[],"synonyms":["cinromide","vumide"],"timeline":[],"approvals":[],"brandName":"Vumide","ecosystem":[],"mechanism":{"target":"Sodium-dependent neutral amino acid transporter B(0)AT1","targets":[{"gene":"SLC6A19","source":"DrugCentral","target":"Sodium-dependent neutral amino acid transporter B(0)AT1","protein":"Sodium-dependent neutral amino acid transporter B(0)AT1"}],"modality":"Small Molecule","explanation":"Think of it like a delivery truck that brings essential nutrients into cells. Vumide blocks this delivery truck, which can help reduce inflammation and other symptoms in certain conditions. By blocking the transport of amino acids, Vumide may help reduce the activity of certain cells that contribute to disease.","oneSentence":"Vumide works by binding to the sodium-dependent neutral amino acid transporter B(0)AT1, which is involved in the transport of certain amino acids across cell membranes.","technicalDetail":"Vumide specifically targets the sodium-dependent neutral amino acid transporter B(0)AT1, a protein responsible for the uptake of neutral amino acids into cells, which plays a crucial role in the regulation of immune responses and inflammation."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3102","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CINROMIDE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T10:03:52.096191","biosimilars":[],"competitors":[{"drugName":"benzatropine","drugSlug":"benzatropine","fdaApproval":"1954-03-05","relationship":"same-target"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"cinromide","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"benzatropine","brandName":"benzatropine","genericName":"benzatropine","approvalYear":"1954","relationship":"same-target"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"UNII":"M197KE7A5N","CHEBI":"CHEBI:135038","INN_ID":"4227","UMLSCUI":"C0055771","ChEMBL_ID":"CHEMBL93233","KEGG_DRUG":"D03513","PUBCHEM_CID":"688145","IUPHAR_LIGAND_ID":"10256","MESH_SUPPLEMENTAL_RECORD_UI":"C018490"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":20,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"recentPublications":[{"date":"2021 Apr 7","pmid":"33825230","title":"Anti-seizure medications for Lennox-Gastaut syndrome.","journal":"The Cochrane database of systematic reviews"},{"date":"2019 Feb","pmid":"30589598","title":"Identification and Characterization of Inhibitors of a Neutral Amino Acid Transporter, SLC6A19, Using Two Functional Cell-Based Assays.","journal":"SLAS discovery : advancing life sciences R & D"},{"date":"1989 Nov-Dec","pmid":"2700841","title":"[Lennox-Gestaut syndrome: therapeutic aspects].","journal":"Rivista di neurologia"},{"date":"1989 Jul-Aug","pmid":"2666120","title":"Double-blind, placebo-controlled evaluation of cinromide in patients with the Lennox-Gastaut Syndrome. The Group for the Evaluation of Cinromide in the Lennox-Gastaut Syndrome.","journal":"Epilepsia"},{"date":"1988","pmid":"2975002","title":"Influence of cinromide on metrazol--induced seizures during ontogenesis in rats.","journal":"Physiologia Bohemoslovaca"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vumide (CINROMIDE) is a small molecule modality targeting the sodium-dependent neutral amino acid transporter B(0)AT1. Its mechanism of action and approved indications are not well-documented, and it is unclear if it has received FDA approval. The commercial status of Vumide is also unknown, with no information available on generic manufacturers or patent status. Further research is needed to understand the pharmacological properties and clinical applications of Vumide. As a result, key safety considerations and pharmacokinetic parameters, such as half-life and bioavailability, are currently unknown.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}